{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T00:07:34.003476+00:00","company":{"ticker":"CGTX","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC"},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"6cee8f15de662fca73dc8c0dc4892c31abf33dd9","cik":1455365,"ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"$(0.05) per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$4.6 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"COGNITION THERAPEUTICS INC reported the first quarter ended March 31, 2026 results: net income $4.6 million, EPS $(0.05) per basic and diluted share.","evidence_excerpt":"expenses\nwas driven primarily by lower stock compensation, compensation and professional fees. Cognition Therapeutics, Inc. www.cogrx.com The Company reported a net loss of $4.6 million, or $(0.05) per\nbasic and diluted share for the first quarter ended March 31, 2026, compared to a net loss of $8.5 million, or $(0.14) per basic and diluted\nshare for the same","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-057186","anchor_url":"https://secwatch.observer/filing/0001104659-26-057186#claim-6cee8f15de662fca73dc8c0dc4892c31abf33dd9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926057186/0001104659-26-057186-index.htm"},{"fact_type":"earnings_release","fact_key":"1ca2fdb90a1ddbef62096e524171af4e197f094b","cik":1455365,"ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2026-03-26T23:59:59+00:00","payload":{"eps_text":"$(0.32) per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$23.5 million, or $(0.32) per basic and diluted share","period_text":"the year ended December 31, 2025","report_date":"2026-03-26","result_type":"reported_results","revenue_text":null},"claim":"COGNITION THERAPEUTICS INC reported the year ended December 31, 2025 results: net income $23.5 million, or $(0.32) per basic and diluted share, EPS $(0.32) per basic and diluted share.","evidence_excerpt":"$12.3 million for 2024. The change in general and administrative\nexpenses was driven primarily by reduced stock-based compensation expenses. The Company reported a net loss of $23.5\nmillion, or $(0.32) per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34.0 million, or\n$(0.86) per basic and diluted share for 2024. Conference","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-034876","anchor_url":"https://secwatch.observer/filing/0001104659-26-034876#claim-1ca2fdb90a1ddbef62096e524171af4e197f094b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926034876/0001104659-26-034876-index.htm"},{"fact_type":"earnings_release","fact_key":"67ec20d123d8dbfe01e67b20ff32cada84766990","cik":1455365,"ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"$(0.27) per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$9.2 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":null},"claim":"COGNITION THERAPEUTICS INC reported first quarter ended March 31, 2024 results: net income $9.2 million, EPS $(0.27) per basic and diluted share.","evidence_excerpt":"The Company reported a net loss of $9.2 million, or $(0.27) per basic and diluted share for the first quarter ended March 31, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-057711","anchor_url":"https://secwatch.observer/filing/0001104659-24-057711#claim-67ec20d123d8dbfe01e67b20ff32cada84766990","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924057711/0001104659-24-057711-index.htm"},{"fact_type":"earnings_release","fact_key":"cb244f8ce235e1de949b19746f060dd2ce512994","cik":1455365,"ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2024-03-26T23:59:59+00:00","payload":{"eps_text":"$(0.86) per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$25.8 million","period_text":"the year ended December 31, 2023","report_date":"2024-03-26","result_type":"reported_results","revenue_text":null},"claim":"COGNITION THERAPEUTICS INC reported the year ended December 31, 2023 results: net income $25.8 million, EPS $(0.86) per basic and diluted share.","evidence_excerpt":"The Company reported a net loss of $25.8 million, or $(0.86) per basic and diluted share for the year ended December 31, 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-038686","anchor_url":"https://secwatch.observer/filing/0001104659-24-038686#claim-cb244f8ce235e1de949b19746f060dd2ce512994","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924038686/0001104659-24-038686-index.htm"},{"fact_type":"material_agreement","fact_key":"602c8a41a4b1ffdf3a701e4c7210912733464c0a","cik":1455365,"ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2024-03-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Titan Partners Group LLC, a division of American Capital Partners, LLC","effective_date":"2024-03-11","item_codes_triggered":["1.01"],"value_text":null},"claim":"COGNITION THERAPEUTICS INC entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2024-03-11).","evidence_excerpt":"On March 11, 2024, Cognition Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell to the Underwriter, in a public offering (the “Offering”), 6,571,428 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”) at a public offering price of $1.75 per share (the “Offering Price”).","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001104659-24-033923","anchor_url":"https://secwatch.observer/filing/0001104659-24-033923#claim-602c8a41a4b1ffdf3a701e4c7210912733464c0a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924033923/0001104659-24-033923-index.htm"},{"fact_type":"earnings_release","fact_key":"e0702209863962c9f55bd9164b428a3dc080e288","cik":1455365,"ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2024-03-11T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $25.6 million","period_text":"the year ended December 31, 2023","report_date":"2024-03-11","result_type":"preliminary_results","revenue_text":null},"claim":"COGNITION THERAPEUTICS INC reported the year ended December 31, 2023 results: net income approximately $25.6 million.","evidence_excerpt":"Preliminary unaudited consolidated operating results for the year ended December 31, 2023 and certain preliminary financial condition information as of December 31, 2023 are as follows: · Net loss for the year ended December 31, 2023 is expected to be approximately $25.6 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-032979","anchor_url":"https://secwatch.observer/filing/0001104659-24-032979#claim-e0702209863962c9f55bd9164b428a3dc080e288","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924032979/0001104659-24-032979-index.htm"}]}